WILLIAMS AND JENSEN, PLLC
Lobbying for PHRMA · Represents country's leading pharmaceutical research and biotechnology companies
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
Issues related to pharmaceutical manufacturing and development.
IP Protections related to trade agreements; trade policies impacting pharmaceutical development; potential tariff actions under Section 232 of the Trade Act of 1962. Legislative proposals related to WTO TRIPS Waiver.